N/A Completed N=22 Treatment

Optical Head-Mounted Display Technology for Low Vision Rehabilitation

Retinal Dystrophies · Healthy

Source: ClinicalTrials.gov NCT02983305 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Oct 2019

Primary outcomePrimary: Change in the Planimetric Area of Goldmann Visual Field With the Use of Head-mounted Display Technology Compared to Baseline (Measured in Degrees Squared) — 563.08; -3799.19 degrees^2 — p=.0001

Summary

The goal of this study is to examine the ability of optical head-mounted display technology to enlarge the visual field of patients with severe visual field loss due to retinal dystrophy and to improve mobility and patient-reported outcomes.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change in the Planimetric Area of Goldmann Visual Field With the Use of Head-mounted Display Technology Compared to Baseline (Measured in Degrees Squared)	563.08; -3799.19	.0001 sig
SECONDARY Change in Gait Speed Compared to Baseline (Measured in Seconds)	-.01; -.01	0.38

Eligibility Criteria

Inclusion criteria for subjects with retinal dystrophy:

diagnosis of retinal dystrophy
severe vision loss that constitutes legal blindness
able to perform a reliable Goldmann visual field test
constricted visual field less than or equal to 20 degrees by Goldmann perimetry using the III4e stimulus in at least one eye with best-corrected visual acuity ≥ 20/60

Inclusion criteria for control subjects:

healthy controls
visit history with the Comprehensive and Pediatric Ophthalmology Services at the University of Michigan
able to perform a reliable Goldmann visual field test

Exclusion criteria for subjects with retinal dystrophy:

movement disorder that precludes evaluation of mobility
functional vision loss
pregnant women

Exclusion criteria for control subjects:

visually significant ocular condition other than correctable refractive error
movement disorder that precludes evaluation of mobility
functional vision loss
pregnant women

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02983305). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.